Associated With Doxorubicin-Induced Cardiotoxicity NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are
نویسندگان
چکیده
Peter Nürnberg, Michael Pfreundschuh, Lorenz Trümper, Jürgen Brockmöller and Gerd Mladen Tzvetkov, Anke Kruger, Silvia Seifert, Marita Kloess, Heidi Hahn, Markus Loeffler, Rosenberger, Stefan Vonhof, Heike Bickeböller, Mohammad Reza Toliat, Eun-Kyung Suk, Leszek Wojnowski, Bettina Kulle, Markus Schirmer, Gregor Schlüter, Albrecht Schmidt, Albert Associated With Doxorubicin-Induced Cardiotoxicity NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 2005 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Circulation doi: 10.1161/CIRCULATIONAHA.105.57685
منابع مشابه
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity.
BACKGROUND A significant number of patients treated with anthracyclines develop cardiotoxicity (anthracycline-induced cardiotoxicity [ACT]), mainly presenting as arrhythmias (acute ACT) or congestive heart failure (chronic ACT). There are no data on pharmacogenomic predictors of ACT. METHODS AND RESULTS We genotyped participants of the German non-Hodgkin lymphoma study (NHL-B) who were follow...
متن کاملDOXORUBICIN AND CPEC INDUCED CARDIOXICITY: association with the GTPase gene Rac2, and drug transporter genes MRP1 and MRP2
Chemotherapy with anthracyclines is associated with cardiotoxicity. Besides known risk factors such as cumulative dose and mediastinal irradiation, there are indications that genetic variation might also be associated with the development of anthracycline induced cardiotoxicity. In the current study a retrospective case control analysis was performed in oncology patients having received anthrac...
متن کاملSchisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling.
PURPOSE The dose-cumulative cardiotoxicities and the emerging cancerous apoptotic/drug resistance are two major obstacles limiting the efficacy of anthracycline antibiotics, notably doxorubicin. We attempted to prove if schisandrin B (Sch B), a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1, could protect against doxorubicin-induced cardiotoxicity, on the premise...
متن کاملA journey in anthracycline-induced cardiotoxicity with emphasizing on doxorubicin: a review article
Cancer is the second leading cause of death in the United States and has become a health problem worldwide. The reported incidence of new cancer cases is estimated at 19.3 million, with a mortality rate of 10 million in the world in 2020. There are several therapeutic approaches for cancer, including chemotherapy. Chemotherapy is consuming anti-neoplastic drugs, alone or in combination. However...
متن کاملDoxorubicin-induced cardiomyopathy: an update beyond oxidative stress and myocardial cell death
The clinical use of doxorubicin is limited by the total cumulative dose due to its dose-related cardiac toxicities. Clinical manifestation of doxorubicin-mediated cardiotoxicity may be presented in forms of arrhythmia, cardiomyopathy, or congestive heart failure. Cardiomyopathy is a condition in which the cardiac muscles are damaged, leading to cardiac dysfunctions. Mechanistically, the damage ...
متن کامل